Gene Therapy Co. Hit With Suit Over $877M Sale To Biogen
A shareholder suit filed Tuesday in Boston federal court accuses London-based gene therapy developer Nightstar Therapeutics of leaving out key information in a regulatory filing about Biogen's plan to buy the...To view the full article, register now.
Already a subscriber? Click here to view full article